Bright Minds Biosciences (DRUG) Research & Development (2020 - 2026)
Bright Minds Biosciences (DRUG) has disclosed Research & Development for 2 consecutive years, with $9.5 million as the latest value for Q1 2026.
- Research & Development reached $9.5 million in Q1 2026 per DRUG's latest filing, up from $1.8 million in the prior quarter.
- Across five years, Research & Development topped out at $9.5 million in Q1 2026 and bottomed at $1.8 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - | 9.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.51 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 748,325.78 |
| Sep 30, 2024 | 304,990.54 |
| Jun 30, 2024 | -414,373.17 |
| Mar 31, 2024 | 78,055.47 |
| Dec 31, 2023 | 900,190.92 |
| Sep 30, 2023 | 814,045.11 |
| Jun 30, 2023 | 782,185.04 |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 1.95 Mn |
| Jun 30, 2022 | 1.61 Mn |
| Mar 31, 2022 | 2.96 Mn |
| Dec 31, 2021 | 3.05 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 2.20 Mn |
| Mar 31, 2021 | 825,599.86 |
| Dec 31, 2020 | 270,610.75 |
| Sep 30, 2020 | 222,106.65 |